ArticleEmerging infectious diseases2025
Short-Lived Neutralizing Antibody Responses to Monkeypox Virus in Smallpox Vaccine-Naive Persons after JYNNEOS Vaccination.
Article in Emerging infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Toward Precision Vaccinology for Mpox: Rational Antigen Design, Next-Generation Platforms, and Immune Correlates of Protection.Tropical medicine and infectious disease · 2026Review
- Extensive cryptic circulation sustains mpox among men who have sex with men.Nature communications · 2026Article
- A comparison of two- and three-dose MVA-BN mpox vaccination series on anti-monkeypox virus immunity.NPJ vaccines · 2026Article
- Viral introductions and return to baseline sexual behaviors maintain low-level mpox incidence in Los Angeles.Nature communications · 2026Article
- An improved and high-throughput mpox virus microneutralization assay.Biosafety and health · 2026Article
- Waning humoral immunity following monkeypox virus infection and vaccination, Canada, 2020 to 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Observational
- Summary of the National Advisory Committee on Immunization (NACI) rapid response: Updated guidance on the use of Imvamune® for the prevention of mpox.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2026Article
- Differentiating mpox infection and vaccination using a validated multiplex orthopoxvirus IgG serology assay.Journal of clinical microbiology · 2026Article
- Conditional T and NK cell antagonism by a giant and highly conserved orthopoxvirus virulence factor.Research square · 2026Article
- Monkeypox Virus Antibodies in Healthy Persons after Vaccination with MVA-BN, United Kingdom.Emerging infectious diseases · 2026Article
- Immune profiling of mpox survivors reveals divergent durability of antibody and T cell responses.Nature communications · 2025Article
- Pro-inflammatory cytokine profiles and neutralizing antibodies in JYNNEOS-vaccinated and mpox-diagnosed individuals.NPJ vaccines · 2025Article
- Efficacy of modified-vaccinia Ankara vaccine as pre- and post-exposure prophylaxis against monkeypox sexual transmission in non-human primate model.Nature communications · 2025Article
- Viral introductions and return to baseline sexual behaviors maintain low-level mpox incidence in Los Angeles County, USA, 2023-2024.medRxiv : the preprint server for health sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
JYNNEOS, a third-generation smallpox vaccine, is integral to monkeypox virus (MPXV) control efforts, but the durability of this modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine's effectiveness is undefined. We optimized and used a plaque reduction neutralization test (PRNT) with authentic clade IIa MPXV and vaccinia virus to assess antibody responses over 12 months in 8 donors vaccinated with 2 doses of JYNNEOS. One donor previously received the ACAM2000 vaccine; 7 donors were smallpox vaccine-naive. IgG responses of the donors to vaccinia virus (L1, B5, and A33) or MPXV (E8, H3, A35) antigens and PRNT titers to both viruses peaked at 8 weeks postvaccination and waned rapidly thereafter in naive donors. MPXV PRNT titers were especially low; no naive donors demonstrated 90% plaque reduction. These data indicate a need for improved correlates of MPXV immunity to enable MVA-BN durability studies, given that recent clinical data support MVA-BN vaccine efficacy against MPXV despite low antibody responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.